Searched over 200M research papers
10 papers analyzed
These studies suggest non-HDL cholesterol is a significant predictor of cardiovascular disease risk, particularly in diabetes patients and for primary prevention, though its predictive value can vary with triglyceride levels and compared to other lipid ratios.
20 papers analyzed
Non-HDL cholesterol is defined as the total cholesterol in the blood minus the high-density lipoprotein (HDL) cholesterol. It includes all the cholesterol contained in lipoproteins that are considered atherogenic, such as very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL), and lipoprotein (a) (Lp(a)), as well as chylomicrons and their remnants.
Non-HDL cholesterol is increasingly recognized as a significant marker for estimating the risk of developing atherosclerotic cardiovascular diseases (ASCVD). Elevated levels of non-HDL cholesterol in adolescence have been strongly linked to the development of ASCVD in adulthood, highlighting its importance in early risk assessment.
While non-HDL cholesterol is a useful predictor of cardiovascular risk, some studies suggest that the total-to-HDL cholesterol ratio might be more informative, especially in specific populations such as those with type 2 diabetes. However, non-HDL cholesterol remains a strong predictor of cardiovascular disease (CVD) in diabetic patients, often outperforming LDL cholesterol and triglycerides alone.
The relationship between non-HDL cholesterol and triglycerides is complex. In conditions like hypertriglyceridemia, non-HDL cholesterol levels can be influenced by the presence of larger, less atherogenic triglyceride-rich lipoproteins. As triglyceride levels increase, non-HDL cholesterol may include more cholesterol from these larger lipoproteins, which are less atherogenic than LDL and remnant lipoproteins. This indicates that triglyceride levels can affect the accuracy of non-HDL cholesterol as a marker for atherogenic lipoproteins.
In diabetic patients with cardiovascular disease, achieving non-HDL cholesterol goals is often suboptimal, particularly at higher triglyceride levels. This is due to the continuous increase in triglyceride-rich lipoproteins, which complicates the attainment of non-HDL cholesterol targets.
Global trends indicate a shift in non-HDL cholesterol levels, with increases observed in low- and middle-income countries, particularly in East and Southeast Asia, and decreases in high-income Western countries. This shift underscores the need for population-based policies and personal interventions to manage cholesterol levels worldwide.
Extended elevations of non-HDL cholesterol across a lifespan are associated with increased cardiovascular risk. Early monitoring of non-HDL cholesterol levels, especially before the age of 40, can help identify individuals at high risk for long-term cardiovascular events, facilitating early preventive measures.
Non-HDL cholesterol is a crucial marker for cardiovascular risk assessment, encompassing all atherogenic lipoproteins. Its levels are influenced by various factors, including triglyceride concentrations, and it serves as a significant predictor of cardiovascular diseases, particularly in diabetic patients. Global trends in non-HDL cholesterol levels highlight the need for targeted interventions to manage cardiovascular risk effectively. Early monitoring and goal attainment are essential for reducing long-term cardiovascular risk associated with elevated non-HDL cholesterol.
Most relevant research papers on this topic